ArticleMedical oncology (Northwood, London, England)2022
5-FU and the dietary flavonoid carvacrol: a synergistic combination that induces apoptosis in MCF-7 breast cancer cells.
Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Natural Products as Modulators of ABC Transporters in Breast Cancer.Phytotherapy research : PTR · 2026Review
- Unlocking synergistic potential: enhancing paclitaxel efficacy in combination with silibinin in breast cancer cell line through H19 LncRNA and P53/Bax/Bcl2 axis.Annals of medicine and surgery (2012) · 2026Article
- Synergistic inhibition of metastatic melanoma by carvacrol and chloroquine: an in vitro and in silico investigation of apoptosis and molecular targets.Medical oncology (Northwood, London, England) · 2026Article
- Combined Cytotoxic Effects of Carvacrol-Based Essential Oil Formulations.Plants (Basel, Switzerland) · 2026Article
- Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells.Oncology research · 2026Article
- Carvacrol as a Therapeutic Candidate in Breast Cancer: Insights into Subtype-Specific Cellular Modulation.Biology · 2025Article
- Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential.Biomolecules · 2025Review
- A dual thermo/pH-sensitive hydrogel as 5-Fluorouracil carrier for breast cancer treatment.Anti-cancer drugs · 2025Article
- Carvacrol protects rats against bleomycin-induced lung oxidative stress, inflammation, and fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Carvacrol and Thymol Hybrids: Potential Anticancer and Antibacterial Therapeutics.Molecules (Basel, Switzerland) · 2024Review
- Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Along with the benefits of chemotherapy in the treatment of breast cancer, the side effects of these drugs along with drug resistance make their use complicated. One of the solutions to overcome this problem is the use of herbal products and combination therapy. In this research, we try to investigate the effects of carvacrol, a monoterpene flavonoid, in combination with the chemotherapy drug 5-FU. Combination index method was used for the drug-drug interactions analysis based on the Chou and Talalay method and the data from MTT assays. Apoptosis was assessed by the ELISA cell death method. P-glycoprotein expression was evaluated at the gene level by Real-time PCR. Here, we described the first experimental evidence for the existence of synergism between carvacrol and 5-FU in the in vitro model of breast cancer. MTT assay results showed combination treatment of the cells with carvacrol and 5-FU decreased 5-FU concentrations significantly. Incubation of the cells with carvacrol neutralized P-glycoprotein overexpression in qPCR assay (P ≤ 0.05). Compared with adding verapamil (a P-glycoprotein inhibitor) to 5-FU, the combination of carvacrol and 5-FU caused a further increase in the percentage of apoptotic cells when the cells were treated with both agents. Our results suggest that carvacrol can downregulate P-gp expression and combination therapy with carvacrol and 5-FU is considered a novel approach to improve the efficacy of chemotherapeutics in cancer patients with high P-glycoprotein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.